# Safety and Tolerability Study of MCI-196

> **NCT01818687** · PHASE3 · TERMINATED · sponsor: **Tanabe Pharma Corporation** · enrollment: 4 (actual)

## Conditions studied

- Chronic Kidney Disease
- Not on Dialysis
- Hyperphosphatemia
- Paediatric

## Interventions

- **DRUG:** colestilan

## Key facts

- **NCT ID:** NCT01818687
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** This study has been terminated because of insufficient patient recruitment.
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01818687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01818687, "Safety and Tolerability Study of MCI-196". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01818687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*